Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark S Cragg

Showing results (1-10 of 178) with videos related to

Pageof 18
Sort By:
Blood|May 5, 2022
(SUMO)-wrestling with rituximabMark S Cragg
Plos Medicine|March 28, 2008
The potential effect of statins on rituximab immunotherapyMark S Cragg
Blood|July 16, 2011
CD20 antibodies: doing the time warpMark S Cragg
Cell Biology International|October 16, 2007
Cancer: a matter of life cycle?Jekaterina Erenpreisa, Mark S Cragg
Nature|November 19, 2020
Engineered antibodies to combat viral threatsXiaojie Yu, Mark S Cragg
Cancer Cell International|September 13, 2013
Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewalJekaterina Erenpreisa, Mark S Cragg
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2018
Deleting Malignant B Cells With Second-Generation Anti-CD20 AntibodiesJosh Sopp, Mark S Cragg
Molecular & Cellular Oncology|June 17, 2016
Death by a thousand knives: Multiple BH3-only proteins are required for maximal apoptosis triggered through the BCRMatthew J Carter, Mark S Cragg
Blood|October 11, 2003
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagentsMark S Cragg, Martin J Glennie
European Journal of Immunology|February 3, 2015
Rehabilitation or the death penalty: autoimmune B cells in the dockLekh N Dahal, Mark S Cragg
Pageof 18

Showing results (1-10 of 178) with videos related to

Sort By:
Pageof 18
Blood|May 5, 2022
(SUMO)-wrestling with rituximabMark S Cragg
Plos Medicine|March 28, 2008
The potential effect of statins on rituximab immunotherapyMark S Cragg
Blood|July 16, 2011
CD20 antibodies: doing the time warpMark S Cragg
Cell Biology International|October 16, 2007
Cancer: a matter of life cycle?Jekaterina Erenpreisa, Mark S Cragg
Nature|November 19, 2020
Engineered antibodies to combat viral threatsXiaojie Yu, Mark S Cragg
Cancer Cell International|September 13, 2013
Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewalJekaterina Erenpreisa, Mark S Cragg
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2018
Deleting Malignant B Cells With Second-Generation Anti-CD20 AntibodiesJosh Sopp, Mark S Cragg
Molecular & Cellular Oncology|June 17, 2016
Death by a thousand knives: Multiple BH3-only proteins are required for maximal apoptosis triggered through the BCRMatthew J Carter, Mark S Cragg
Blood|October 11, 2003
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagentsMark S Cragg, Martin J Glennie
European Journal of Immunology|February 3, 2015
Rehabilitation or the death penalty: autoimmune B cells in the dockLekh N Dahal, Mark S Cragg
Pageof 18